Claims for Patent: 6,087,129

Summary for Patent: 6,087,129

Title:	Recombinant expression of proteins from secretory cell lines
Abstract:	The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.
Inventor(s):	Newgard; Christopher B. (Dallas, TX), Normington; Karl D. (Dallas, TX), Clark; Samuel A. (Rockwall, TX), Thigpen; Anice E. (Dallas, TX), Quaade; Christian (Dallas, TX), Kruse; Fred (Dallas, TX)
Assignee:	Betagene, Inc. (Dallas, TX) Board of Regents, The University of Texas System (Austin, TX)
Application Number:	08/589,028
Patent Claims:	1. A method for the production of a polypeptide comprising the steps of: (a) providing a eukarvotic secretory host cell; (b) inhibiting the production of an endogenous, secreted polypeptide; (c) transforming said secretory host cell with an exogenous polynucleotide comprising a gene encoding an exogenous polypeptide, wherein said gene is under the control of a promoter active in eukaryotic cells; and (d) culturing said secretory host cell under conditions such that said exogenous polynucleotide expresses said exogenous polypeptide; wherein steps (a)-(c) are performed in vitro. 2. The method of claim 1, wherein said promoter is selected from the group consisting of CMV, SV40 IE, RSV LTR, GAPDH and RIP1. 3. The method of claim 1, wherein said exogenous polynucleotide further comprises an adenovirus tripartite 5' leader sequence and intron. 4. The method of claim 3, wherein said intron comprises the 5' donor site of the adenovirus major late transcript and the 3' splice site of an immunoglobulin gene. 5. The method of claim 1, wherein said exogenous polynucleotide further comprises a polyadenylation signal. 6. The method of claim 1, wherein said eukaryotic secretory host cell is a neuroendocrine cell. 7. The method of claim 6, wherein said neuroendocrine cell is an insulinoma cell. 8. The method of claim 7, wherein said insulinoma cell is a rat insulinoma cell. 9. The method of claim 7, wherein said insulinoma cell is a human insulinoma cell. 10. The method of claim 1, wherein said exogenous polypeptide is secreted. 11. The method of claim 10, wherein said exogenous polypeptide is a fusion protein. 12. The method of claim 11, wherein said fusion protein comprises a leader sequence that is not naturally associated with said exogenous polypeptide. 13. The method of claim 10, wherein said exogenous polypeptide is amidated. 14. The method of claim 13, wherein said amidated polypeptide is selected from the group consisting of calcitonin, calcitonin gene related peptide (CGRP), .beta.-calcitonin gene related peptide, hypercalcemia of malignancy factor (1-40) (PTH-rP), parathyroid hormone-related protein (107-139) (PTH-rP), parathyroid hormone-related protein (107-111) (PTH-rP), cholecystokinin (27-33) (CCK), galanin message associated peptide, preprogalanin (65-105), gastrin I, gastrin releasing peptide, glucagon-like peptide (GLP-1), pancreastatin, pancreatic peptide, peptide YY, PHM, secretin, vasoactive intestinal peptide (VIP), oxytocin, vasopressin (AVP), vasotocin, enkephalins, enkephalinamide, metorphinamide (adrenorphin), alpha melanocyte stimulating hormone (alpha-MSH), atrial natriuretic factor (5-28) (ANF), amylin, amyloid P component (SAP-1), corticotropin releasing hormone (CRH), growth hormone releasing factor (GHRH), luteinizing hormone-releasing hormone (LHRH), neuropeptide Y, substance K (neurokinin A), substance P and thyrotropin releasing hormone (TRH). 15. The method of claim 10, wherein said exogenous polypeptide is a hormone. 16. The method of claim 15, wherein said hormone is selected from the group consisting of growth hormone, prolactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, chorionic gonadotropin, thyroid-stimulating hormone, adrenocorticotropin (ACTH), angiotensin I, angiotensin II, .beta.-endorphin, .beta.-melanocyte stimulating hormone (.beta.-MSH), cholecystokinin, endothelin I, galanin, gastric inhibitory peptide (GIP), glucagon, insulin, lipotropins, neurophysins and somatostatin. 17. The method of claim 1, wherein said endogenous, secreted polypeptide and said exogenous polypeptide are the same. 18. The method of claim 1, wherein said exogenous polypeptide enhances the production and/or secretion of at least one polypeptide produced by said cell. 19. The method of claim 1, wherein said step (c) further comprises contacting said secretory host cell with a polynucleotide comprising a gene for a selectable marker and step (d) further comprises culturing under drug selection, wherein steps (a)-(d) are performed in vitro. 20. The method of claim 19, wherein said selectable marker gene is flanked by LoxP sites. 21. The method of claim 20, further comprising: (e) transforming the eukarmotic secretory host cell with a polynucleotide encoding the Cre protein, wherein said polynucleotide is under the control of a promoter active in eukaryotic cells; and (f) replicate culturing said cell with and without drug selection; wherein steps (a)-(f) are performed in vitro. 22. The method of claim 19, wherein said selectable marker is neomycin and said drug is G418. 23. The method of claim 19, wherein the genes for said exogenous polypeptide and said selectable marker are part of the same polynucleotide. 24. The method of claim 1, wherein said eukarvotic secretory host cell is glucose-responsive. 25. The method of claim 1, wherein said inhibiting of production of said endogenous, secreted polypeptide is effected by interruption of the gene encoding said endogenous, secreted polypetpide. 26. The method of claim 25, wherein said interruption is effected by homologous recombination.

Details for Patent 6,087,129

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2039-02-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2039-02-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2039-02-26
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2039-02-26
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2039-02-26
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2039-02-26